Fredun Pharmaceuticals Ltd Share Price – BSE

Pharmaceuticals, Small Cap

The board of Fredun Pharmaceuticals at its meeting held on 29 December 2025 has approved allotment of 6,44,360 equity shares at an issue price of Rs 1250 (including a premium of Rs 1240) on preferential basis for a cash consideration of Rs 80.54 crore payable in cash;

The board also approved allotment of 5,51,600 convertible warrants at an exercise price of Rs 1250 per warrant aggregating to Rs 68.95 crore, upon receipt of Rs 312.50 (being 25% of the issue price of warrant) amounting to Rs 17.23 crore as subscription price.

Powered by Capital Market - Live News

Net profit of Fredun Pharmaceuticals rose 127.87% to Rs 9.73 crore in the quarter ended September 2025 as against Rs 4.27 crore during the previous quarter ended September 2024. Sales rose 34.33% to Rs 143.59 crore in the quarter ended September 2025 as against Rs 106.89 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News

Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 8 November 2025.

Powered by Capital Market - Live News

The product, launched under Fredun's Freossi brand, is free from root vegetables, meat, and animal-derived ingredients, in line with Jain dietary principles. It is designed to support pet immunity, digestion, bone health, and energy.

Snacky Jain will be initially available in six cities through veterinary clinics, online platforms, and retail partners, with expansion planned for Ahmedabad, Pune, Bengaluru, and Delhi.

The product is manufactured at the company?s WHO-GMP-certified Palghar facility. Fredun said the launch strengthens its position in India's pet healthcare market, estimated at Rs 10,000 crore and growing at over 22% annually.

Fredun Pharmaceuticals, a healthcare and pharmaceuticals company offer a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. The company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.

On a standalone basis, Fredun Pharmaceuticals' net profit rose 63.92% to Rs 6.77 crore while net sales rose 53.99% to Rs 119.40 crore in Q1 June 2025 over Q1 June 2024.

Powered by Capital Market - Live News